Oxidative Medicine and Cellular Longevity / 2021 / Article / Tab 3 / Research Article
Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines Table 3 Preliminary screening of the cytotoxic efficacy of the synthesized chalcone-thienopyrimidine derivatives 3a-g against human liver cancer cell line (HepG2) compared to DMSO. The cytotoxic efficacy of the compounds is expressed as the mean of survival percentage ± SEM.
Compound concentration (μ g/ml) 3a 3b 3c 3d 3e 3f 3g DMSO 10000 18.5 ± 0.001 12.1 ± 0.002 18.0 ± 0.001 18.4 ± 0.002 14.1 ± 0.002 10.7 ± 0.004 12.3 ± 0.002 10.6 ± 0.018 5000 19.1 ± 0.001 12.1 ± 0.001 18.8 ± 0.001 18.5 ± 0.003 16.8 ± 0.003 11.6 ± 0.002 12.5 ± 0.001 11.2 ± 0.001 2500 19.5 ± 0.001 12.2 ± 0.001 19.0 ± 0.002 19.4 ± 0.004 17.4 ± 0.002 11.7 ± 0.009 12.7 ± 0.002 11.6 ± 0.028 1250 20.5 ± 0.004 12.7 ± 0.002 20.1 ± 0.004 19.5 ± 0.001 18.4 ± 0.003 12.6 ± 0.019 12.5 ± 0.001 14.4 ± 0.028 625 21.7 ± 0.012 12.9 ± 0.006 20.6 ± 0.003 20.0 ± 0.001 18.9 ± 0.001 15.3 ± 0.005 13.0 ± 0.003 14.4 ± 0.061 312.5 28.4 ± 0.009 13.3 ± 0.004 21.1 ± 0.004 20.5 ± 0.002 19.8 ± 0.005 77.8 ± 0.071 14.1 ± 0.002 44.4 ± 0.012 156.25 40.1 ± 0.021 16.2 ± 0.004 22.1 ± 0.011 20.5 ± 0.002 21.1± 0.012 112.0 ± 0.460 14.5 ± 0.003 103.6 ± 0.051 78.125 66.9 ± 0.018 17.3 ± 0.007 62.4 ± 0.051 31.0 ± 0.017 21.4 ± 0.073 115.9 ± 0.157 17.5 ± 0.002 109.4 ± 0.040 39.0625 73.8 ± 0.019 18.4 ± 0.006 63.0 ± 0.030 91.2 ± 0.138 45.1 ± 0.072 119.1 ± 0.122 64.1 ± 0.038 113.6 ± 0.052 19.53125 74.2 ± 0.012 23.2 ± 0.012 69.8 ± 0.027 99.2 ± 0.026 91.9 ± 0.060 144.7 ± 0.140 97.8 ± 0.053 118 ± 0.045 9.765625 87.8 ± 0.087 67.9 ± 0.048 81.6 ± 0.027 111.0 ± 0.041 114.3 ± 0.141 149.1 ± 0.106 115.9 ± 0.098 174.4 ± 0.129 4.8828125 103.5 ± 0.033 110.1 ± 0.046 91.5 ± 0.013 123.0 ± 0.026 127.5 ± 0.033 149.7 ± 0.200 131.3 ± 0.033 183.0 ± 0.078